ReviewJournal of clinical medicine2021

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.

María Rosario García Campelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.